Ecor1 Capital, Llc, Ten Percent Owner at Eiger Biopharmaceuticals, holds 13.44M shares in Zymeworks (Ticker: ZYME), holds 3.85M shares in Voyager Therapeutics (Ticker: VYGR), holds 23.17M shares in Prothena (Ticker: PRTA). Most recently, Ecor1 Capital, Llc Bought ― shares of Zymeworks on Jun 21, 2023 for an estimated value of 27.20M.
Ecor1 Capital, Llc latest transaction was an Informative Buy of $27.20M.
What was Ecor1 Capital, Llc's most profitable transaction?
Ecor1 Capital, Llc’s most profitable transaction was an Informative Sell of CRVS stock on October 1, 2021. The return on the trade was 82.90%.
What is Ecor1 Capital, Llc's role in Eiger Biopharmaceuticals?
Ecor1 Capital, Llc's role in Eiger Biopharmaceuticals is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.